• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Sana Biotechnology Inc. (Amendment)

    2/9/24 5:35:30 PM ET
    $SANA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $SANA alert in real time by email
    SC 13G/A 1 arch-sch13g_18793.htm ARCH VENTURE FUND IX, L.P. - SANA BIOTECHNOLOGY -- SCH 13G/A(#2)

     

      

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

     

     

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934

      (Amendment No. 2)*

     

     

     

     

    Sana Biotechnology, Inc.

    (Name of Issuer)

       

    Common Stock par value $0.0001 per share

     

    (Title of Class of Securities)

      

    799566104

     

    (CUSIP Number)

      

    December 31, 2023

     

    (Date of Event Which Requires Filing of This Statement)

     

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

    ☐   Rule 13d-1(b)

    ☐   Rule 13d-1(c)

    ☒   Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act, but shall be subject to all other provisions of the Act (however, see the Notes).

     

     
     

    CUSIP No.  799566104

    13G Page 2 of 25 Pages    

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Fund IX, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    44,042,500

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    44,042,500

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    44,042,500

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    22.3%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    PN

     

       

     
     

     

    CUSIP No.  799566104

    13G Page 3 of 25 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Fund IX Overage, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    44,042,500

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    44,042,500

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    44,042,500

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    22.3%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    PN

     

       

     
     

    CUSIP No.  799566104

    13G Page 4 of 25 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Fund X, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    44,042,500

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    44,042,500

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    44,042,500

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    22.3%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    PN

     

       

     
     

    CUSIP No.  799566104

    13G Page 5 of 25 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Fund X Overage, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    44,042,500

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    44,042,500

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    44,042,500

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    22.3%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    PN

     

       

     
     

    CUSIP No.  799566104

    13G Page 6 of 25 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Partners IX, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    44,042,500

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    44,042,500

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    44,042,500

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    22.3%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    PN

     

       

     
     

     

    CUSIP No.  799566104

    13G Page 7 of 25 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Partners IX Overage, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    44,042,500

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    44,042,500

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    44,042,500

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    22.3%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    PN

     

       

     
     

     

    CUSIP No.  799566104

    13G Page 8 of 25 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Partners X Overage, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    44,042,500

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    44,042,500

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    44,042,500

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    22.3%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    PN

     

       

     
     

    CUSIP No.  799566104

    13G Page 9 of 25 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Partners X, L.P.

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    44,042,500

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    44,042,500

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    44,042,500

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    22.3%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    PN

     

       

     
     

    CUSIP No.  799566104

    13G Page 10 of 25 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Partners IX, LLC

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    44,042,500

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    44,042,500

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    44,042,500

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    22.3%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    OO

     

       

     
     

    CUSIP No.  799566104

    13G Page 11 of 25 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    ARCH Venture Partners X, LLC

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    Delaware

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    44,042,500

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    44,042,500

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    44,042,500

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    22.3%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    OO

     

       

     

     

    CUSIP No.  799566104

    13G Page 12 of 25 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    Keith Crandell

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    44,042,500

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    44,042,500

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    44,042,500

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    22.3%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    IN

     

       

     
     

    CUSIP No.  799566104

    13G Page 13 of 25 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    Clinton Bybee

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    44,042,500

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    44,042,500

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    44,042,500

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    22.3%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    IN

     

       

     
     

    CUSIP No.  799566104

    13G Page 14 of 25 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    Robert Nelsen

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    102,444

     

      6  

    SHARED VOTING POWER

     

    44,042,500

     

      7  

    SOLE DISPOSITIVE POWER

     

    102,444

     

      8  

    SHARED DISPOSITIVE POWER

     

    44,042,500

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    44,144,944

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    22.4%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    IN

     

       

     
     

    CUSIP No.  799566104

    13G Page 15 of 25 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    Steven Gillis

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    44,042,500

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    44,042,500

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    44,042,500

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    22.3%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    IN

     

       

     
     

    CUSIP No.  799566104

    13G Page 16 of 25 Pages    

     

    1  

    NAMES OF REPORTING PERSON(S)

     

    Kristina Burow

     

       
    2  

    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP

     

     

     

     

    (a) ☐

    (b) ☐

    3  

    SEC USE ONLY

     

     

     

       
    4  

    CITIZENSHIP OR PLACE OF ORGANIZATION

     

    United States of America

      

       
    NUMBER OF
    SHARES
    BENEFICIALLY
    OWNED BY EACH
    REPORTING
    PERSON WITH
     

     5

     

    SOLE VOTING POWER

     

    0

     

      6  

    SHARED VOTING POWER

     

    44,042,500

     

      7  

    SOLE DISPOSITIVE POWER

     

    0

     

      8  

    SHARED DISPOSITIVE POWER

     

    44,042,500

     

    9  

    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

    44,042,500

     

       
    10  

    CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES

     

     

     

       ☐
    11  

    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

      

    22.3%

     

       

     12

     

    TYPE OF REPORTING PERSON

       

    IN

     

       
     
     

    CUSIP No.  799566104

    13G Page 17 of 25 Pages    

     

     

    Item 1(a). Name of Issuer

     

    Sana Biotechnology, Inc. (the “Issuer”).

     

     

    Item 1(b). Address of Issuer's Principal Executive Offices

     

    188 East Blaine Street, Suite 400, Seattle, WA 98102

     

     

    Item 2(a). Name of Person Filing

     

    ARCH Venture Fund IX, L.P. (“AVF IX”); ARCH Venture Partners IX, L.P. (“AVP IX LP”); ARCH Venture Partners IX, LLC (“AVP IX LLC”); ARCH Venture Fund IX Overage, L.P. (“AVF IX Overage”); ARCH Venture Partners IX Overage, L.P. (“AVP IX Overage GP”); ARCH Venture Fund X, L.P. (“AVF X”); ARCH Venture Partners X, L.P. (“AVP X LP”); ARCH Venture Fund X Overage, L.P. (“AVF X Overage”); ARCH Venture Partners X Overage, L.P. (“AVP X Overage GP”); ARCH Venture Partners X, LLC (“AVP X LLC”); (collectively, the “Reporting Entities” and individually, each a “Reporting Entity”); and Keith Crandell (“Crandell”), Robert Nelsen (“Nelsen”) and Clinton Bybee (“Bybee”) (collectively, the “Managing Directors” and individually, each a “Managing Director”), and Steven Gillis (“Gillis”) and Kristina Burow (“Burow”), along with Nelsen and Crandell, collectively the “Investment Committee”; individually “Committee members”. The Reporting Entities, Managing Directors and the Investment Committee members collectively are referred to as the “Reporting Persons”. 

     

     

    Item 2(b). Address of Principal Business Office or, if none, Residence

     

    8755 W. Higgins Road, Suite 1025, Chicago, IL 60631

     

     

    Item 2(c). Citizenship

     

    Each of AVF IX, AVP IX LP, AVF IX Overage, AVP IX Overage GP, AVF X, AVP X LP, AVF X Overage and AVP X Overage GP are limited partnerships organized under the laws of the State of Delaware. AVP IX LLC and AVP X LLC are each a limited liability company organized under the laws of the State of Delaware. Each Managing Director and Committee Member is a US citizen.

     

     

    Item 2(d). Title of Class of Securities

     

    Common stock, par value $0.0001 per share.

     

     

    Item 2(e). CUSIP Number

     

    799566104

     

      

    Item 3. If this statement is filed pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a:

     

    Not Applicable.

     

     
     

    CUSIP No.  799566104

    13G Page 18 of 25 Pages    

     

    Item 4. Ownership

     

    (a)

    Amount beneficially owned:

     

    AVF IX is the record owner of 10,303,750 shares of Common Stock (the “AVF IX Shares”) as of December 31, 2023. AVP IX LP, as the sole general partner of AVF IX, may be deemed to beneficially own the AVF IX Shares.

     

    AVF IX Overage is the record owner of 10,301,250 shares of Common Stock (the “AVF IX Overage Shares”) as of December 31, 2023. AVP IX Overage GP, as the sole general partner of AVF IX Overage, may be deemed to beneficially own the AVF IX Overage shares, combined with AVF IX Shares (the “IX Record Shares”) as of December 31, 2023.

     

    AVF X is the record owner of 11,718,750 shares of Common Stock (the “AVF X Shares”) as of December 31, 2023. AVP X LP, as the sole general partner of AVF X, may be deemed to beneficially own the AVF X Shares.

     

    AVF X Overage is the record owner of 11,718,750 shares of Common Stock (the “AVF X Overage Shares”) as of December 31, 2023. AVP X Overage GP, as the sole general partner of AVF X Overage, may be deemed to beneficially own the AVF X Overage Shares, combined with AVF X Shares (the “X Record Shares”) as of December 31, 2023.

     

    AVP IX LLC, as the sole general partner of AVP IX LP and AVP IX Overage GP, may be deemed to beneficially own the IX Record Shares. As managing directors of AVP IX LLC, each Managing Director may also be deemed to share the power to direct the disposition and vote of the IX Record Shares.

     

    AVP X LLC, as the sole general partner of AVP X LP and AVP X Overage GP, may be deemed to beneficially own the X Record Shares. As Investment Committee Members of AVP X LLC, each Committee Member may also be deemed to share the power to direct the disposition and vote of the X Record Shares.

     

    In addition, as of December 31, 2023, Nelsen is a holder of options to purchase 88,591 shares of Common Stock (the “Vested Option Shares”) and 1,353 fully vested restricted stock units (“RSUs”) and Enzo Family Trust of 2015, the beneficiaries of which are members of Nelsen’s family, holds 12,500 shares of common stock.

     

    (b)

    Percent of class:

     

    See line 11 of the cover sheets. The percentages set forth on the cover sheet for each Reporting Person (other than Nelsen) is based upon 197,133,208 shares of common stock outstanding as of October 31, 2023 as reported on the Issuer’s Form 10-Q as filed with the Securities and Exchange Commission on November 8, 2023. For Nelsen, the Vested Option Shares were included in the number of shares of Common Stock outstanding.

     

       

     
     

    CUSIP No.  799566104

    13G Page 19 of 25 Pages    

     

     

    (c) Number of shares as to which such person has:
         
      (i)

    Sole power to vote or to direct the vote:

     

    See line 5 of the cover sheets.

         
      (ii)

    Shared power to vote or to direct the vote:

     

    See line 6 of the cover sheets.

         
      (iii)

    Sole power to dispose or to direct the disposition:

     

    See line 7 of the cover sheets.

         
      (iv)

    Shared power to dispose or to direct the disposition:

     

    See line 8 of the cover sheets.

         

    Each Reporting Person disclaims beneficial ownership of such shares of Common Stock except for the shares, if any, such Reporting Person holds of record.

     

    Item 5. Ownership of Five Percent or Less of a Class

    Not Applicable.

     

     

    Item 6. Ownership of More than Five Percent on Behalf of Another Person

     

    Not Applicable.

     

     

    Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

     

    Not Applicable.

     

     

    Item 8. Identification and Classification of Members of the Group

     

    Not Applicable.

     

     

    Item 9. Notice of Dissolution of Group

     

    Not Applicable.

     

     

    Item 10. Certifications

     

    Not Applicable.

      

     
     

    CUSIP No.  799566104

    13G Page 20 of 25 Pages    

     

     

    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     

    Dated:    February 9, 2024

    ARCH VENTURE FUND IX, L.P.

     

    By:       ARCH Venture Partners IX, L.P.

    its General Partner

     

    By:      ARCH Venture Partners IX, LLC

    its General Partner

     

    By:                     *                         

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS IX, L.P.

     

    By:       ARCH Venture Partners IX, LLC

    its General Partner

     

    By:                                *                           

         Keith Crandell

         Managing Director

     

    ARCH VENTURE PARTNERS IX, LLC

     

    By:                                       *                                

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE FUND IX OVERAGE, L.P.

     

    By:       ARCH Venture Partners IX Overage, L.P.

    its General Partner

     

    By:      ARCH Venture Partners IX, LLC

    its General Partner

     

    By:                     *                         

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS IX OVERAGE, L.P.

     

    By:       ARCH Venture Partners IX, LLC

    its General Partner

     

    By:                     *                         

    Keith Crandell

    Managing Director

     

     

     

     
     

    CUSIP No.  799566104

    13G Page 21 of 25 Pages    

     

     

     

     

     

     

    ARCH VENTURE FUND X, L.P.

     

    By:       ARCH Venture Partners X, L.P.

    its General Partner

     

    By:      ARCH Venture Partners X, LLC

    its General Partner

    By:                     *                         

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS X, L.P.

     

    By:       ARCH Venture Partners X, LLC

    its General Partner

     

    By:                                *                           

         Keith Crandell

         Managing Director

     

     

    ARCH VENTURE PARTNERS X, LLC

     

    By:                                       *                                

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE FUND X OVERAGE, L.P.

     

    By:       ARCH Venture Partners X Overage, L.P.

    its General Partner

     

    By:      ARCH Venture Partners X, LLC

    its General Partner

     

    By:                     *                         

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS X OVERAGE, L.P.

     

    By:       ARCH Venture Partners X, LLC

    its General Partner

     

    By:                               *                           

        Keith Crandell

        Managing Director

     

     

     

     

     
     

    CUSIP No.  799566104

    13G Page 22 of 25 Pages    

     

     

     

     

     

     

     

                                         *                                          

    Keith Crandell

     

     

                                         *                                          

    Robert Nelsen

     

     

                                         *                                          

    Clinton Bybee

     

     

                                         *                                          

    Kristina Burow

     

     

                                         *                                          

    Steven Gillis

     

     

     

     

     

     

     

     

     

     

    * By:       /s/ Mark McDonnell       

    Mark McDonnell as

    Attorney-in-Fact

     

     

    *       This Schedule 13G was executed by Mark McDonnell pursuant to Powers of Attorney filed as Exhibit 24.0 and Exhibit 24.1 to the Form 3 relating to the beneficial ownership of shares of Sana Biotechnology, Inc. by certain of the Reporting Persons filed with the Securities and Exchange Commission on February 3, 2021 and incorporated herein in its entirety by reference and Powers of Attorney filed as Exhibit 24 to the Form 3 relating to the beneficial ownership of shares of Gossamer Bio, Inc. by certain of the Reporting Persons filed with the Securities and Exchange Commission on February 7, 2019 and incorporated herein in its entirety by reference.

     

     

     

     

     
     

    CUSIP No.  799566104

    13G Page 23 of 25 Pages    

     

     

    Exhibit 1

     

    AGREEMENT

     

     

    Pursuant to Rule 13d-1-(k)(1) under the Securities Exchange Act of 1934, the undersigned hereby agree that only one statement containing the information required by Schedule 13G need be filed with respect to the ownership by each of the undersigned of shares of stock of Sana Biotechnology, Inc.

     

    This Agreement may be executed in any number of counterparts, each of which shall be deemed an original.

     

     

    Dated:    February 9, 2024

    ARCH VENTURE FUND IX, L.P.

     

    By:       ARCH Venture Partners IX, L.P.

    its General Partner

     

    By:       ARCH Venture Partners IX, LLC

    its General Partner

     

    By:                     *                         

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS IX, L.P.

     

    By:       ARCH Venture Partners IX, LLC

    its General Partner

     

    By:                                *                           

         Keith Crandell

         Managing Director

     

    ARCH VENTURE PARTNERS IX, LLC

     

    By:                                       *                                

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE FUND IX OVERAGE, L.P.

     

    By:        ARCH Venture Partners IX Overage, L.P.

    its General Partner

     

    By:       ARCH Venture Partners IX, LLC

    its General Partner

     

    By:                     *                         

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS IX OVERAGE, L.P.

     

    By:       ARCH Venture Partners IX, LLC

    its General Partner

     

    By:                     *                         

    Keith Crandell

    Managing Director

     

     
     

    CUSIP No.  799566104

    13G Page 24 of 25 Pages    

     

     

     

     

     

     

    ARCH VENTURE FUND X, L.P.

     

    By:        ARCH Venture Partners X, L.P.

    its General Partner

     

    By:      ARCH Venture Partners X, LLC

    its General Partner

    By:                     *                         

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS X, L.P.

     

    By:       ARCH Venture Partners X, LLC

    its General Partner

     

    By:                                *                           

         Keith Crandell

         Managing Director

     

     

    ARCH VENTURE PARTNERS X, LLC

     

    By:                                       *                                

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE FUND X OVERAGE, L.P.

     

    By:        ARCH Venture Partners X Overage, L.P.

    its General Partner

     

    By:      ARCH Venture Partners X, LLC

    its General Partner

     

    By:                     *                         

    Keith Crandell

    Managing Director

     

     

    ARCH VENTURE PARTNERS X OVERAGE, L.P.

     

    By:       ARCH Venture Partners X, LLC

    its General Partner

     

    By:                               *                           

        Keith Crandell

        Managing Director

     

     

     

     

     
     

    CUSIP No.  799566104

    13G Page 25 of 25 Pages    

     

     

     

     

     

     

                                         *                                          

    Keith Crandell

     

     

                                         *                                          

    Robert Nelsen

     

     

                                         *                                          

    Clinton Bybee

     

     

                                         *                                          

    Kristina Burow

     

     

                                         *                                          

    Steven Gillis

     

     

     

     

    * By:       /s/ Mark McDonnell       

    Mark McDonnell as

    Attorney-in-Fact

     

     

    *             This Agreement of Joint Filing was executed by Mark McDonnell pursuant to Powers of Attorney filed as Exhibit 24.0 and Exhibit 24.1 to the Form 3 relating to the beneficial ownership of shares of Sana Biotechnology, Inc. by certain of the Reporting Persons filed with the Securities and Exchange Commission on February 3, 2021 and incorporated herein in its entirety by reference and Powers of Attorney filed as Exhibit 24 to the Form 3 relating to the beneficial ownership of shares of Gossamer Bio, Inc. by certain of the Reporting Persons filed with the Securities and Exchange Commission on February 7, 2019 and incorporated herein in its entirety by reference.

     

     

     

     

     

     

     

     

     

     

     

     

     

     

     

    Get the next $SANA alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $SANA

    DatePrice TargetRatingAnalyst
    7/3/2025$12.00Overweight
    Morgan Stanley
    3/18/2025$5.00Mkt Perform → Mkt Outperform
    Citizens JMP
    3/14/2025$7.00Buy
    Jefferies
    1/8/2025Hold → Buy
    TD Cowen
    11/5/2024Mkt Outperform → Mkt Perform
    JMP Securities
    6/26/2024$16.00Buy
    Rodman & Renshaw
    1/16/2024$12.00Neutral → Buy
    H.C. Wainwright
    9/25/2023$9.00Mkt Outperform
    JMP Securities
    More analyst ratings

    $SANA
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Morgan Stanley resumed coverage on Sana Biotechnology with a new price target

      Morgan Stanley resumed coverage of Sana Biotechnology with a rating of Overweight and set a new price target of $12.00

      7/3/25 7:51:55 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sana Biotechnology upgraded by Citizens JMP with a new price target

      Citizens JMP upgraded Sana Biotechnology from Mkt Perform to Mkt Outperform and set a new price target of $5.00

      3/18/25 7:56:06 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Jefferies initiated coverage on Sana Biotechnology with a new price target

      Jefferies initiated coverage of Sana Biotechnology with a rating of Buy and set a new price target of $7.00

      3/14/25 7:41:20 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    SEC Filings

    See more
    • Sana Biotechnology Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Sana Biotechnology, Inc. (0001770121) (Filer)

      6/23/25 10:10:46 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sana Biotechnology Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders

      8-K - Sana Biotechnology, Inc. (0001770121) (Filer)

      6/6/25 4:05:17 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 424B5 filed by Sana Biotechnology Inc.

      424B5 - Sana Biotechnology, Inc. (0001770121) (Filer)

      5/8/25 4:44:44 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Director Bishop Hans Edgar was granted 7,842 shares, increasing direct ownership by 0.13% to 5,828,955 units (SEC Form 4)

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      7/8/25 4:17:31 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Rosiello Robert L.

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      6/9/25 4:40:33 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4 filed by Director Bilenker Joshua H.

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      6/9/25 4:40:28 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • Nelsen Robert bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      2/12/24 5:46:20 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Crandell Keith bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      2/12/24 5:43:56 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Arch Venture Fund X, L.P. bought $9,999,996 worth of shares (1,818,181 units at $5.50) (SEC Form 4)

      4 - Sana Biotechnology, Inc. (0001770121) (Issuer)

      2/12/24 5:43:09 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    Leadership Updates

    Live Leadership Updates

    See more
    • Ted Myles Joins Cellarity as Chief Executive Officer

      Myles, a Biopharma Industry Veteran, Will Also Join Flagship Pioneering as a CEO-Partner CAMBRIDGE, Mass., May 12, 2025 /PRNewswire/ -- Cellarity, a life sciences company transforming the way medicines are created, and Flagship Pioneering, the bioplatform innovation company, today announced the appointment of Ted Myles as Chief Executive Officer of Cellarity and CEO-Partner at Flagship. Myles is a seasoned biopharma leader with deep experience and a track record for building clinical and commercial-stage companies. Previously, he was Chief Financial Officer and Chief Operating

      5/12/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Flagship Pioneering Appoints Rahul Kakkar as CEO-Partner and CEO of Quotient Therapeutics

      CAMBRIDGE, Mass., April 29, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, and Quotient Therapeutics, a company pioneering somatic genomics, today announced that Rahul Kakkar, M.D., will join Flagship Pioneering as CEO-Partner and Quotient Therapeutics as Chief Executive Officer. Dr. Kakkar is a biotech entrepreneur and physician-scientist with nearly 20 years of professional experience founding and building biotechnology companies and practicing medicine. Previously, he served as President and CEO of Tome Biosciences, a genome engineering biotec

      4/29/25 8:00:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Sana Biotechnology Reports Fourth Quarter and Full Year 2024 Financial Results and Business Updates

      Announced positive preliminary 12-week clinical results, building on already released 4-week results, of ongoing type 1 diabetes study showing that hypoimmune-modified pancreatic islet cells transplanted without immunosuppression overcome autoimmune and allogeneic immune recognition, function, and persist with stable C-peptide production post-transplant Enrolling patients in the GLEAM trial for SC291 in B-cell mediated autoimmune diseases and VIVID trial for SC262 in relapsed/refractory B-cell malignancies; expect to report clinical data from both studies in 2025 Presented preclinical data in non-human primates showing safety and deep B cell depletion using a surrogate for SG299, an in viv

      3/17/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/14/24 5:12:32 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/14/24 6:00:14 AM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Sana Biotechnology Inc.

      SC 13G/A - Sana Biotechnology, Inc. (0001770121) (Subject)

      11/12/24 4:52:24 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    Financials

    Live finance-specific insights

    See more
    • Sana Biotechnology Announces Positive Clinical Results from Type 1 Diabetes Study of Islet Cell Transplantation Without Immunosuppression

      First-in-Human Study Provides Evidence that Sana's Hypoimmune (HIP) Technology Enables Transplanted Islet Cells to Avoid Immune Rejection and Produce Insulin Without Immunosuppression Results Demonstrate HIP-Engineered Primary Pancreatic Islet Cells Avoid Immune Detection, Function, and Persist after Intramuscular Transplantation in First Treated Patient with Type 1 Diabetes Function and Persistence of Pancreatic Islets Were Detectable by Production of Consistent Levels of Circulating C-Peptide, a Marker of Insulin Production, and Increased C-Peptide Levels with a Mixed Meal Tolerance Test (MMTT) MRI Shows Signals Consistent with Graft Survival 28 Days after Transplantation Study Contin

      1/7/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $SANA
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Flagship Pioneering Unveils Terrana Biosciences to Deliver Adaptive, Targeted Agricultural Solutions through a Novel RNA Technology Platform

      Solutions focus on enhancing crop resilience, protecting yields, and addressing critical challenges in the global food system The company emerges after four years of platform development with an initial commitment of $50 million from Flagship Pioneering CAMBRIDGE, Mass., July 1, 2025 /PRNewswire/ -- Flagship Pioneering, the bioplatform innovation company, today unveiled Terrana Biosciences™, a company pioneering RNA-based agricultural solutions to deliver protective and enhanced crop traits without altering the plant genome. Through its proprietary RNA technology platform, Terrana is developing targeted products designed to work at any time in a plant's lifecycle, enabling a continuous prod

      7/1/25 6:30:00 AM ET
      $FHTX
      $MRNA
      $SANA
      Biotechnology: Pharmaceutical Preparations
      Health Care
      Biotechnology: Biological Products (No Diagnostic Substances)
    • Sana Biotechnology Announces Invited Oral Presentation at the 85th Annual American Diabetes Association Scientific Sessions

      SEATTLE, June 09, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced an upcoming podium presentation highlighting ongoing clinical data from the investigator-sponsored, first-in-human study transplanting UP421, an allogeneic primary islet cell therapy engineered with Sana's hypoimmune (HIP) technology, into a patient with type 1 diabetes without the use of any immunosuppression. The presentation will be held during a joint American Diabetes Association (ADA)/International Pancreas & Islet Transplant Association (IPITA) symposium at the 85th Annual ADA Scientific Sessions taking p

      6/9/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Sana Biotechnology to Present at June 2025 Investor Conferences

      SEATTLE, May 28, 2025 (GLOBE NEWSWIRE) -- Sana Biotechnology, Inc. (NASDAQ:SANA), a company focused on changing the possible for patients through engineered cells, today announced that it will webcast its presentations at two investor conferences in June. The presentations will feature a business overview and update. Sana will present at the Jefferies Global Healthcare Conference at 2:35 p.m. ET on Wednesday, June 4, 2025.Sana will present at the Goldman Sachs 46th Annual Global Healthcare Conference at 8:40 a.m. ET on Tuesday, June 10, 2025. The webcasts will be accessible on the Investor Relations page of Sana's website at https://sana.com/. A replay of each presentation will be availa

      5/28/25 4:05:00 PM ET
      $SANA
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care